Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions

Phase

TERMINATED

Status

394

Enrollment

INDUSTRY

Sponsor class

Stopped The NEVO™ stent will not be commercialized. Cordis have decided to close the study after 3 years. This decision took the absence of safety signals into account.

Conditions

Coronary Atherosclerosis

Interventions

DEVICE: NEVO™ Sirolimus-eluting Coronary Stent System
DEVICE: Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)

Sponsor

Cordis US Corp.

Collaborators

[object Object]